Prior Authorizations Are Top Burden For Medical Groups: MGMA

Prior authorization is the most burdensome regulatory issue facing medical groups, with 89% saying it is very or extremely burdensome, according to a Nov. 13 report from the Medical Group Management Association.

The MGMA’s annual regulatory report surveyed executives from more than 350 group practices, according to the report. Sixty percent of respondents are in practices with fewer than 20 physicians and 16 percent are in practices with more than 100 physicians. Seventy-five percent of respondents are in independent practices.

According to the report, 97 percent of leaders surveyed said their patients have experienced delays or denials for medically necessary care due to prior authorization requirements. Ninety-two percent said their practice has hired or redistributed staff to work on prior authorizations due to the increase in requests.

Leaders said the top challenges are delays in prior authorization decisions (88%), prior authorizations for routinely approved items and services (83%), and inconsistent payer payment policies (80%).

 

Source Link

Recommended Articles

New NFIB Survey: Small Businesses Report Reduced Optimism

The NFIB Small Business Optimism Index fell 0.6 points in May to 95.3, remaining below its 52-year average of 98.0. The Uncertainty Index rose 3 points from April to 91, remaining well above its historical average of 68. As reported in NFIB’s monthly Jobs Report, the NFIB Small Business Employment Index remained essentially flat, registering 100.3 in May. ...

Read More

Trump Announces TrumpRx Expansion, Adding 160 More Drugs

President Trump on Friday announced that over 100 prescription medications would be added to his administration’s direct-to-consumer drug platform, TrumpRx, the second expansion of the initiative in as many months. “I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs,” ...

Read More

Skyrocketing GLP-1 Demand Creates Major Financial Strain For Employers

GLP-1 drugs are a double-edged sword for the nation’s employers. Although they are having a demonstrable effect on workplace health, the high cost is putting a strain on their budgets. GLP-1s, known by brand names such as Ozempic, Wegovy, Mounjaro or Zepbound, originally were developed to help regulate blood sugar in people with Type 2 ...

Read More

Judge Throws Out Policy Imposing $100,000 Fees for Skilled Worker Visas

A Trump administration initiative to impose $100,000 fees on employers seeking visas for skilled foreign workers amounts to an unlawful tax on those companies and must be voided “in its entirety,” a federal judge ruled on Monday. The decision by Judge Leo T. Sorokin of the Federal District Court for the District of Massachusetts nullified ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square